Kamyar Neshvadian

Kamyar_Neshvadian

NomoCan Pharmaceuticals

2014-2015

Affiliations

State University of New York

Technologies

Therapeutic

Indication

Basic Research

Drug Discovery

Molecular Diagnostic

Oncology

Orphan Diseases

Personalized Medicine

Executive Summary

View/Download

Utilizing a novel immunologic approach, NomoCan Pharmaceuticals is developing a targeted therapy for the treatment and prognosis of the most aggressive human cancer, pancreatic cancer.

Newsletter Signup

Corporate Supporters